A new drug that 'melts' away cancer has been given fast-track
approval in the US. Developed in Melbourne, Australia, Venetoclax was
developed to specifically target chronic lymphocytic leukaemia.
The drug showed a positive result in 80% of clinical trials, with one in five patients finishing the programme completely cancer-free. Venetoclax is administered orally every day via a pill.
In the original trial, 116 participants increased their dosage from 20mg to 400mg over a five-week period.
The drug showed a positive result in 80% of clinical trials, with one in five patients finishing the programme completely cancer-free. Venetoclax is administered orally every day via a pill.
In the original trial, 116 participants increased their dosage from 20mg to 400mg over a five-week period.
No comments:
Post a Comment